Cheetah Digital Debuts Next Generation Personalization Solution at Signals 2020
10.11.2020 20:00:00 EET | Business Wire | Press release
Cheetah Digital, a cross-channel customer engagement solution provider for the modern marketer, today announces Cheetah Personalization at Signals 2020. This next-generation personalization solution is the newest addition to the Cheetah Customer Engagement Suite that includes the Cheetah Engagement Data Platform, Experiences, Messaging, and Loyalty. Cheetah Personalization helps marketers orchestrate real-time interactions across all channels and touchpoints.
To remain competitive in today’s signal-saturated world, marketers need to deliver relevant, personalized content throughout the customer journey. Ninety-one percent of consumers are more likely to shop with brands who recognize, remember, and provide relevant offers and recommendations. Furthermore, real-time offers and content can be 10 times more effective than traditional outbound marketing campaigns.
“Personalization is in the fabric of everything marketers do. But as a strategy, technology and a market, personalization is ripe for reinvention,” said Sameer Kazi, CEO at Cheetah Digital. “We wanted to create a technology blueprint for brands to achieve personalization success. With Cheetah Digital, the next-generation of personalization is here. It’s the way forward for marketers to achieve their personalization, and ultimately business, goals.”
Organizations need technology to orchestrate each aspect of personalization, from data to distribution, in order to unlock the full power of personalization. With cookies and third-party data no longer being viable options for marketers, first and zero-party data are at the core of next-generation personalization.
Cheetah Personalization leverages analytics and machine learning to evaluate every customer on an individual level to derive the right content, offer, channel and sequence for a customer journey. The new solution includes delivering the next-best experience, next-best journey and next-best offers. These capabilities are enabled by three key product offerings:
- Cheetah Real-Time Personalization: Allows you to engage with customers in real-time with targeted experiences by capturing streaming data on web and mobile.
- Cheetah Journey Designer: Gives marketers the power to build, manage and optimize multi-step, multi-stage customer journeys at scale.
- Cheetah Intelligent Offers: Applies marketing insights and machine learning to optimize experiences and generate the next best offer and next best action.
“Personalization is one of the most critical themes for our customers and organization,” said Bill Ingram, Chief Product Officer at Cheetah Digital. “It’s not about guesswork, cookies or third-party data. The next generation of personalization is about providing a value exchange for consumers in the “moment” when you have them on your mobile app, on your site, in your store, where you can provide them something that will generate trust and affinity with the brand. With the data foundation of the Engagement Data Platform, we are well equipped to deliver a first class, next-generation personalization solution.”
“We were tasked with making better use of our data for more effective personalization for our guests in the face of a rapidly changing landscape,” said Katie Rhine, Corporate Marketing Manager at SeaWorld. “With Cheetah Digital’s solution, we were able to leverage zero-party data from email and deliver a more relevant and personalized experience for our guests. Now, we can personalize experiences at scale and create loyal customers across all our locations.”
This follows Cheetah Digital’s recent recognition in the MarTech Breakthrough Awards, where it was named Best Enterprise CRM Solution. To learn more about these updates and the new Cheetah Personalization solution, visit cheetahdigital.com/solutions/cheetah-personalization.
About Cheetah Digital
Cheetah Digital is a cross-channel customer engagement solution provider for the modern marketer. The Cheetah Digital Customer Engagement Suite enables marketers to create personalized experiences, cross-channel messaging, and loyalty strategies, underpinned by an engagement data platform that can scale to meet the changing demands of today's consumer. Many of the world’s best brands, including Hilton, Neiman Marcus, Walgreens, and Williams-Sonoma trust Cheetah Digital to help them drive revenue, build lasting customer relationships, and deliver a unique value exchange throughout the customer lifecycle. To learn more, visit www.cheetahdigital.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201110005797/en/
Contact information
BLASTmedia for Cheetah Digital
cheetahdigital@blastmedia.com
317-806-1900
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom